If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.16    -0.0105 (-6.16%)
Bid:
0.15
Ask:
0.17
Spread: 0.02 (13.333%)
Market Cap: £2.11m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Result of EGM

11 Jan 2006 13:09

For immediate release 11 January 2006 Azure Holdings Plc ("Azure" or the "Company") Result of EGM At an extraordinary general meeting of the Company held yesterday, allresolutions were duly passed. The EGM was convened in order to give thedirectors authority to allot shares pursuant to sections 80 and 89 of theCompanies Act 1985. The primary purpose was to provide the directors of theCompany with the necessary authorities to enable Mr Roger Taylor, a Swiss basedprivate investor, to subscribe for ‚£330,000 nominal of convertible unsecuredloan stock ("CULS"), convertible into 66,000,000 new ordinary shares in thecapital of the Company. Existing ordinary shareholders were also provided withthe opportunity to subscribe for up to ‚£100,000 nominal of CULS on the sameterms.The Company has received an application for ‚£330,000 nominal of CULS from MrTaylor. In addition, applications were received from existing ordinaryshareholders for ‚£15,000 nominal of CULS.The CULS are convertible on the basis of 200 new ordinary shares in Azure forevery ‚£1 nominal of CULS, repayable on 31 December 2006 and may be converted inthe following circumstances: * the CULS holder has served a conversion notice; or * a reverse takeover, as defined by the AIM rules, occurs; and * the Panel on Takeovers and Mergers has granted a waiver of the obligation under rule 9 of the City Code on Takeovers and Mergers which may arise following conversion of the CULS and that waiver has been approved by a vote of independent shareholders in general meeting; and * the CULS are converted in tranches of ‚£1,000 nominal. Enquiries:Azure Holdings PlcNicolas Greenstone 020 7258 5140John East & Partners LimitedJohn East 020 7628 2200ENDAZURE HOLDINGS PLC
Date   Source Headline
22nd Jun 20267:00 amRNSConclusion of Evaluation with University of Dundee
22nd Jun 20267:00 amRNSFinal Results & Notice of AGM
2nd Jun 20267:00 amRNSConclusion of Evaluation with Stingray
1st Jun 20267:00 amRNSValiRx Exercises Option on Evaluation Asset
27th May 20267:00 amRNSCytolytix Patent Granted
21st May 20267:00 amRNSResult of Oversubscribed WRAP Retail Offer
18th May 20267:00 amRNSWRAP Retail Offer for up to £150,000
15th May 20267:00 amRNSFundraising of up to £1,155,000
31st Mar 202610:15 amRNSChange of Registered Office
26th Mar 20267:00 amRNSValiRx Commercial Update Q1 2026
24th Mar 20267:00 amRNSValiRx and TwinEdge to present Digital Twin data
4th Mar 20267:00 amRNSDirector/PDMR Shareholding
2nd Mar 20267:00 amRNSValiRx forms ValiRx Animal Health Ltd subsidiary
19th Jan 20267:00 amRNSExercise of Warrants
9th Jan 20263:45 pmRNSReplacement: Evaluation and Transfer Agreement
9th Jan 20267:00 amRNSNew Evaluation and Material Transfer Agreement
8th Jan 20261:00 pmRNSHolding(s) in Company
5th Dec 202510:56 amRNSHolding(s) in Company
24th Nov 20253:54 pmRNSHolding(s) in Company
24th Nov 20259:30 amRNSHolding(s) in Company
20th Nov 202512:11 pmRNSResult of GM & Issue of Equity
13th Nov 20252:16 pmRNSHolding(s) in Company
10th Nov 20257:00 amRNSHolding(s) in Company
4th Nov 20255:15 pmRNSPosting of Circular and Notice of General Meeting
4th Nov 20257:00 amRNSResult of WRAP Retail Offer
30th Oct 20257:21 amRNSWRAP Retail Offer for up to £300,000
30th Oct 20257:17 amRNSFundraising of up to £1,050,000
14th Oct 20257:00 amRNSInaphaea Commercial update
29th Sep 20257:00 amRNSHalf-year Report
18th Sep 20257:00 amRNSInaphaea Commercial Update
1st Sep 20257:00 amRNSCytolytix Commercial update
26th Aug 20257:00 amRNSCommercial update
7th Aug 202510:51 amRNSValiRx Awarded Grant from Open University
5th Aug 20259:53 amRNSUpdate on Evaluation Agreement with Stingray Bio
4th Aug 20257:00 amRNSLicensing Agreement with Dominion Biotech Ltd
29th Jul 20257:00 amRNSCollaboration Agreement with Voxcell BioInnovation
30th Jun 20253:48 pmRNSResult of AGM
20th Jun 20257:00 amRNSAmbrose Exercise Option on VAL401
9th Jun 202510:57 amRNSValiRx Investor Webinar
6th Jun 202510:54 amRNSHolding(s) in Company
6th Jun 20257:00 amRNSFinal Results & Notice of AGM
3rd Jun 20257:00 amRNSNew Evaluation and Material Transfer Agreement
20th May 20251:25 pmRNSHolding(s) in Company
12th May 20257:00 amRNSInaphaea Deal Extension With Dominion
30th Apr 20257:00 amRNSCommercial Update
3rd Apr 20257:00 amRNSTermination of Letter of Intent with TheoremRx
27th Mar 20257:00 amRNSDirectorate Changes and new Advisory Board
21st Mar 202511:07 amRNSDirector Disclosure Update
24th Feb 20257:00 amRNSConclusion of Evaluation Project
3rd Feb 20257:00 amRNSInaphaea Evaluation and Commercial Use Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.